Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Birutė Galdikas: The last of the ‘angels’ in primatology’s most extraordinary chapter - 2Lucrative Positions in the Advancing Position Market of 2024
- 3Find Your Internal Culinary expert: Cooking Strategies and Recipes
- 4Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- 5South African radio presenter among five charged over Russia recruitment plot
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- The Green Transformation: 5 Feasible Living Practices
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- Ways to track down the Right Criminal Legal counselor
- Merz: 80% of Syrians in Germany expected to return within three years
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Five held on suspicion of planning attack on German Christmas market
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Dental Embed Developments: Upsetting Current Dentistry
